Final Rx Labeling Rule Should Not Preempt State Product Liability Laws, States Say
This article was originally published in The Pink Sheet Daily
National Conference of State Legislatures alleges that FDA’s final labeling rule will include language limiting state product liability laws.
You may also be interested in...
Generic product liability suits are on the rise, which could result in more generic drug makers arguing for federal preemption, Bradshaw says.
Five former top agency lawyers say filing of amicus briefs in product liability cases is a longstanding practice that predates current Chief Counsel Dan Troy. Rep. Hinchey's justification for shifting $500,000 out of the chief counsel's budget "cannot be supported," the lawyers tell Congress.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications